Trial Condition(s):

Atrial Fibrillation

Xarelto for prevention of stroke in patients with atrial fibrillation in Latinamerica and EMEA region (XANTUS-EL)

Bayer Identifier:

16691

ClinicalTrials.gov Identifier:

NCT01800006

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This international study is a prospective noninterventional observational cohort study of patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Patients will be followed up for 1 year or until 30 days after end of rivaroxaban therapy in case of therapy was discontinued earlier than 12 months. Serious adverse events will be followed up adequately. Laboratory values (e.g., Hb, HCT, haemoccult) should be documented for each point in time they were measured.

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
Inclusion Criteria:
  - Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS systemic embolism, and who consent to participate in the study.

Trial Summary

Enrollment Goal
2101
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Kazakhstan

Status
Completed
 
Locations

Investigative Site

Many Locations, Russia

Status
Completed
 
Locations

Investigative Site

Many Locations, Venezuela

Status
Completed
 
Locations

Investigative Site

Many Locations, Mexico

Status
Completed
 
Locations

Investigative Site

Many Locations, Uruguay

Status
Completed
 
Locations

Investigative Site

Many Locations, Kenya

Status
Completed
 
Locations

Investigative Site

Many Locations, Egypt

Status
Completed
 
Locations

Investigative Site

ManyLocations, Saudi Arabia

Status
Completed
 
Locations

Investigative Site

ManyLocations, Jordan

Status
Completed
 
Locations

Investigative Site

ManyLocations, Lebanon

Status
Completed
 
Locations

Investigative Site

Many Locations, United Arab Emirates

Status
Completed
 
Locations

Investigative Site

Many Locations, Argentina

Status
Completed
 
Locations

Investigative Site

Many Locations, Chile

Status
Completed
 
Locations

Investigative Site

Many Locations, Bahrain

Status
Completed
 
Locations

Investigative Site

Many Locations, Azerbaijan

Status
Completed
 
Locations

Investigative Site

Many Locations, Colombia

Status
Completed
 
Locations

Investigative Site

Many Locations, Georgia

Status
Completed
 

Trial Design